Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Nile Therapeutics |
---|---|
Information provided by: | Nile Therapeutics |
ClinicalTrials.gov Identifier: | NCT00557661 |
An open-label study designed to determine the safety, tolerability and pharmacodynamics of CD-NP infusions in heart failure patients.
Condition | Intervention | Phase |
---|---|---|
Congestive Heart Failure |
Drug: CD-NP |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study |
Official Title: | A Multi-Center, Ascending Dose Trial to Assess the Safety, Pharmacokinetics and Pharmacodynamics of CD-NP Infusions in Patients With Congestive Heart Failure |
Estimated Enrollment: | 30 |
Study Start Date: | November 2007 |
Estimated Study Completion Date: | November 2008 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Key Inclusion Criteria:
Key Exclusion Criteria:
Contact: Jennifer Hodge | jhodge@nilethera.com |
United States, Minnesota | |
DaVita Clinical Research | Recruiting |
Minneapolis, Minnesota, United States, 55404 |
Principal Investigator: | Steven Goldsmith, MD | Hennepin County Medical Center - Minneapolis |
Study ID Numbers: | NIL-CDNP-CT002 |
Study First Received: | November 12, 2007 |
Last Updated: | October 19, 2008 |
ClinicalTrials.gov Identifier: | NCT00557661 |
Health Authority: | United States: Food and Drug Administration |
Heart failure CD-NP |
Heart Failure Heart Diseases |
Cardiovascular Diseases |